The Role of IL33/ST2 Axis in ARDS Patients

February 24, 2019 updated by: Hospital Universitari Vall d'Hebron Research Institute
The main objective is the study of the role of IL33/ST2 axis in the pathogenesis of ARDS, it´s value as prognosis marker and as therapeutic target.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08035
        • Hospital Universitary Vall d´Hebron

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with ARDS criteria according to Berlin definition or risk pathologies

Description

Inclusion Criteria:

  • ARDS
  • Risk pathologies to develop ARDS (sepsis, pancreatitis, pneumonia, massive transfussion, politraumatics)

Exclusion Criteria:

  • Age under 18
  • Pregnancy
  • Undergoing a clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Survivors
Non survivors

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prognostic value of the IL-33/ST2 axis in patients with ARDS.
Time Frame: 60 days
60 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Value of IL33/ST2 axis to predict development of ARDS in risk patients
Time Frame: 60 days
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Actual)

July 1, 2015

Study Completion

December 1, 2019

Study Registration Dates

First Submitted

July 3, 2015

First Submitted That Met QC Criteria

July 3, 2015

First Posted (Estimate)

July 8, 2015

Study Record Updates

Last Update Posted (Actual)

February 26, 2019

Last Update Submitted That Met QC Criteria

February 24, 2019

Last Verified

January 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IL33/ST2

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Respiratory Distress Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe